Janice Yeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Janice Yeh has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Farshad Foroudi
Department of Radiation Oncology, Olivia Newton‐John Cancer Wellness & Research Centre Austin Health Heidelberg Victoria Australia
4 shared publicationsMark Tacey
Department of Radiation Oncology, Olivia Newton‐John Cancer Wellness & Research Centre Austin Health Heidelberg Victoria Australia
3 shared publications- Michael Chao
Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Australia
3 shared publications - Eddie Lau
Department of Radiology and Molecular Imaging Therapy Austin Health Heidelberg Victoria Australia
2 shared publications - Jenny Sim
Department of Medical Imaging and Radiation Sciences Monash University Clayton Victoria Australia
2 shared publications Sweet Ping Ng
Department of Radiation Oncology Olivia Newton-John Cancer Wellness & Research Centre Austin Health Victoria Australia; Department of Medical Imaging and Radiation Sciences, Monash University Clayton Victoria Australia
2 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
Appearance of Stabilised Hyaluronic Acid Gel on Routine Surveillance Breast Imaging When Used to Mark the Post‐Lumpectomy Tumour Bed in Breast Cancer
Introduction: Stabilised hyaluronic acid (sHA) gel can be used as a breast cancer tumour bed marker. This study aimed to assess the gel on post‐treatment surveillance mammography (MMG) and breast ultrasound (USS). Methods: Patients who underwent breast‐conserving surgery and adjuvant radiotherapy, with sHA gel markers (0.3–0.5 mL drops) in breast tissue had their routine 1‐ and 2‐year post‐treatment MMG and USS undergo central review by one experienced radiologist. The central review questionnaire included whether the gel was visible, description if visible, and whether it impacted diagnostic assessment of the images using a 5‐point Likert scale. The images were also standardly reported by radiologists who were blinded to the gel history. Results: Of the 33 patients eligible for evaluation, sHA gel was visible on the 1‐year post‐treatment MMG in 3% of patients, described as well circumscribed nodules adjacent to the surgical scar. sHA gel was visible on the 1‐year post‐treatment USS in 38% of patients, described as simple round cystic lesions near the surgical bed. sHA gel was still visible on the same patient's 2‐year post‐treatment MMG (3%) and was visible on the 2‐year post‐treatment USS in 19% of patients. In all cases, the gel was rated ‘unlikely’ or ‘very unlikely’ to impair diagnostic assessment of the images and did not lead to any additional investigations. The blinded radiologists reported the gel as non‐suspicious appearing cysts without clinical concern. Conclusion: sHA gel used as breast tumour bed marker was not visible in most patients' post‐treatment MMG and USS and did not affect diagnostic assessment.
- 8 September 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
Open AccessAppearance of Stabilised Hyaluronic Acid Gel on Routine Surveillance Breast Imaging When Used to Mark the Post‐Lumpectomy Tumour Bed in Breast Cancer
Introduction: Stabilised hyaluronic acid (sHA) gel can be used as a breast cancer tumour bed marker. This study aimed to assess the gel on post‐treatment surveillance mammography (MMG) and breast ultrasound (USS). Methods: Patients who underwent breast‐conserving surgery and adjuvant radiotherapy, with sHA gel markers (0.3–0.5 mL drops) in breast tissue had their routine 1‐ and 2‐year post‐treatment MMG and USS undergo central review by one experienced radiologist. The central review questionnaire included whether the gel was visible, description if visible, and whether it impacted diagnostic assessment of the images using a 5‐point Likert scale. The images were also standardly reported by radiologists who were blinded to the gel history. Results: Of the 33 patients eligible for evaluation, sHA gel was visible on the 1‐year post‐treatment MMG in 3% of patients, described as well circumscribed nodules adjacent to the surgical scar. sHA gel was visible on the 1‐year post‐treatment USS in 38% of patients, described as simple round cystic lesions near the surgical bed. sHA gel was still visible on the same patient's 2‐year post‐treatment MMG (3%) and was visible on the 2‐year post‐treatment USS in 19% of patients. In all cases, the gel was rated ‘unlikely’ or ‘very unlikely’ to impair diagnostic assessment of the images and did not lead to any additional investigations. The blinded radiologists reported the gel as non‐suspicious appearing cysts without clinical concern. Conclusion: sHA gel used as breast tumour bed marker was not visible in most patients' post‐treatment MMG and USS and did not affect diagnostic assessment.
- 27 January 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 205, 110749
Stabilised hyaluronic acid gel marker versus surgical clips for tumour bed delineation in breast cancer radiotherapy using MRI-simulation
- 27 January 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 205, 110749
Stabilised hyaluronic acid gel marker versus surgical clips for tumour bed delineation in breast cancer radiotherapy using MRI-simulation
- Open Access
- 19 February 2024
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 45, 100745
Stabilised Hyaluronic Acid (sHA) gel as a novel marker for breast cancer tumour bed cavity: Surgical feasibility
- 19 February 2024
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 45, 100745
Open AccessStabilised Hyaluronic Acid (sHA) gel as a novel marker for breast cancer tumour bed cavity: Surgical feasibility
- Open Access
- 25 January 2022
- Published by MedCrave Group Kft. in International Journal of Radiology & Radiation Therapy
- Vol. 9 (1) , 6-12
Retrospective dosimetric comparison of VMAT versus t-IMRT for patients with carbon dioxide tissue expanders undergoing left sided PMRT using the recent ESTRO-ACROP target volume delineation
Introduction: The Aeroform tissue expander device (ATED) is a novel alternative system for patients who have had mastectomy for breast cancer (BC) and require adjuvant radiation therapy (RT), and investigations are required when used during RT. We aim to compare RT dosimetry outcomes using volumetric modulated arc therapy (VMAT) versus tangential intensity-modulated radiation therapy (t-IMRT) techniques when planning post-mastectomy RT (PMRT), using the recent European Society for Radiation Oncology – Advisory Committee on Radiation Oncology Practice (ESTRO-ACROP) target volume delineation consensus guideline.1 Methods: Five patients with left-sided BC undergoing PMRT with ATED in-situ were identified. Retrospectively, their CT-simulation scans were utilised to delineate the chest wall (CW) and nodal target volumes. A dose of 50.4Gy in 28 fractions was prescribed and four plans generated. Dosimetry for all target volumes and organs at risk were extracted, with paired means compared. Results: When comparing VMAT with t-IMRT techniques, there was no statistically significant difference in the PTV50.4 D95% or D2% coverage. Within t-IMRT plans, excluding internal mammary nodes (IMN) leads to higher D95% coverage. The heart mean dose and V25 were significantly lower with VMAT than t-IMRT. There was no significant difference to the heart dose whether IMN was included or not. The ipsilateral lung V20 was significantly lower with VMAT than t-IMRT, but not the V5. Within t-IMRT plans, excluding IMN leads to lower ipsilateral lung V20. The t-IMRT plans had lower contralateral lung V5, and even lower when IMN was not included. The contralateral breast mean dose was not significantly different between VMAT and t-IMRT. Within t-IMRT plans, the right breast mean dose was lower if IMN was excluded. Conclusion: We have not shown a clear advantage of VMAT over t-IMRT techniques when prescribing PMRT for left-sided BC patients with ATED in-situ.
- 25 January 2022
- Published by MedCrave Group Kft. in International Journal of Radiology & Radiation Therapy
- Vol. 9 (1) , 6-12
Open AccessRetrospective dosimetric comparison of VMAT versus t-IMRT for patients with carbon dioxide tissue expanders undergoing left sided PMRT using the recent ESTRO-ACROP target volume delineation
Introduction: The Aeroform tissue expander device (ATED) is a novel alternative system for patients who have had mastectomy for breast cancer (BC) and require adjuvant radiation therapy (RT), and investigations are required when used during RT. We aim to compare RT dosimetry outcomes using volumetric modulated arc therapy (VMAT) versus tangential intensity-modulated radiation therapy (t-IMRT) techniques when planning post-mastectomy RT (PMRT), using the recent European Society for Radiation Oncology – Advisory Committee on Radiation Oncology Practice (ESTRO-ACROP) target volume delineation consensus guideline.1 Methods: Five patients with left-sided BC undergoing PMRT with ATED in-situ were identified. Retrospectively, their CT-simulation scans were utilised to delineate the chest wall (CW) and nodal target volumes. A dose of 50.4Gy in 28 fractions was prescribed and four plans generated. Dosimetry for all target volumes and organs at risk were extracted, with paired means compared. Results: When comparing VMAT with t-IMRT techniques, there was no statistically significant difference in the PTV50.4 D95% or D2% coverage. Within t-IMRT plans, excluding internal mammary nodes (IMN) leads to higher D95% coverage. The heart mean dose and V25 were significantly lower with VMAT than t-IMRT. There was no significant difference to the heart dose whether IMN was included or not. The ipsilateral lung V20 was significantly lower with VMAT than t-IMRT, but not the V5. Within t-IMRT plans, excluding IMN leads to lower ipsilateral lung V20. The t-IMRT plans had lower contralateral lung V5, and even lower when IMN was not included. The contralateral breast mean dose was not significantly different between VMAT and t-IMRT. Within t-IMRT plans, the right breast mean dose was lower if IMN was excluded. Conclusion: We have not shown a clear advantage of VMAT over t-IMRT techniques when prescribing PMRT for left-sided BC patients with ATED in-situ.